strongest `BUY` in the market - 500 Beiträge pro Seite

[silberco]

Schaut Euch mal BBII an! Pressure Cycling Technology nähert
sich der Marktreife ... it`s time to act IMO !!!
WKN 904312 wird u.A. im Yahoo message board diskutiert ...

[silberco]

Finance Home - Yahoo! - Help






[ Latest Headlines | Market Overview | News Alerts ]


Thursday April 26, 1:51 pm Eastern Time

Press Release

SOURCE: Boston Biomedica, Inc.

Boston Biomedica Announces
Development of Novel Sample
Processing Procedure

Proprietary Process Using PCT to be Presented at Boston Genomics
Conference

WEST BRIDGEWATER, Mass., April 26 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq:
BBII - news) announced today that Dr. Feng Tao, Project Scientist in the Company`s Pressure
Cycling Technology (PCT) research group, will present data this afternoon at Cambridge
Healthtech Institute`s Genomic Sample Preparation Conference in Boston on BBI`s novel system
for the extraction of nucleic acids (DNA and RNA) from cells and tissues. Dr. Tao`s talk, entitled
Pressure Cycling Technology (PCT)-Based Nucleic Acid Sample Preparation for Diagnostics and
Genomics, will address a new method for releasing nucleic acids from a variety of biological
samples. The system combines Boston Biomedica`s patented PCT technology with patent-pending
devices to efficiently prepare nucleic acid samples from cells and tissues. This process represents a
new and exciting approach to solving a difficult laboratory problem, and offers potentially important
advantages for proteomics and nucleic acid testing in many fields, including research and industrial
applications in agriculture, medicine, pharmaceuticals and biotechnology.

The PCT sample preparation system utilizes a unique combination of pressure and temperature in
BBI`s ultra-high pressure BAROCYCLER(TM) instrument to efficiently release cellular contents
while maintaining the integrity and biological activity of the molecules liberated, and in significantly
less time than standard laboratory techniques. Since this process does not require the use of
detergents or harsh chemicals, the initial product can be used directly as a source of nucleic acids
for many research applications, or can be further processed to obtain more highly purified
materials. The products prepared by the PCT sample processing system can also be used for
analysis and purification of other biological molecules such as proteins, carbohydrates, lipids and
various metabolites.

``Our novel PCT sample processing system generates high quality cellular component preparations
in a few minutes, thus eliminating the slow and labor- intensive methods commonly used for
hard-to-lyse cell and tissue sample processing,`` commented Richard T. Schumacher, Founder,
CEO, and Chairman of Boston Biomedica. ``We are very excited by the results of these studies,
and believe that this work may lead to the release of our first commercial PCT product.``

Boston Biomedica, Inc. provides products and services for the detection and monitoring of
infectious diseases such as AIDS and Viral Hepatitis. BBI has three operating business units: (1)
BBI Diagnostics, an ISO 9001 certified manufacturer and supplier of quality control and
diagnostics reagents used to increase the accuracy of in vitro diagnostic tests, (2) BBI Biotech
Research Laboratories, a research and development center providing R&D support for the other
BBI business units, as well as contract research and repository services for the government,
industry and other third parties, and (3) BBI Source Scientific, an ISO 9001 certified manufacturer
of diagnostic instrumentation and medical devices. In addition, BBI is conducting research and
development in Pressure Cycling Technology (PCT) through its subsidiary BBI BioSeq, with the
goal of introducing new solutions for a number of important healthcare issues, including: inactivation
of pathogens in human plasma, extraction of nucleic acids, food safety, and genomics. BBI also
maintains a passive investment in Panacos Pharmaceuticals, a privately held antiviral drug and
vaccine development company recently spun-out from BBI, whose goal is to introduce new
solutions for the treatment of infectious diseases.

Statements contained in this news release that state the Company`s or management`s intention,
hopes, beliefs, expectations or predictions of the future are ``forward-looking`` statements. It is
important to note that the Company`s actual results could differ materially from those projected in
such forward-looking statements. Factors that could cause actual results to differ from those
projected include the possibility that, due to difficulties in the development of the technology, BBI
may not be successful in developing pressure cycling technology into commercially viable products
or services; that the PCT sample processing system may never become a better alternative than
current methods for biomolecular purification or nucleic acid isolation; that pressure cycling
technology may not be adaptable to any other commercially viable applications; that certain
pressure cycling applications may not fall within the claims of the Company`s four issued patents;
and that individuals and groups utilizing such PCT procedures may not be required to license such
technology from BBI. Additional information concerning factors that could cause actual results to
differ materially from those in the forward-looking statements is contained from time to time in the
Company`s SEC filing including, but not limited to, the Company`s annual report on Form 10-K for
the year ended December 31, 2000 and quarterly reports on Form 10-Q for the periods ended
March 31, June 30 and September 30, 2000. Copies of these documents may be obtained by
contacting the Company or the SEC.

Visit us at our website http://www.bbii.com

Please email us at [e-mail] if you prefer to receive future announcements electronically

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X73215386

SOURCE: Boston Biomedica, Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:
Boston Biomedica Inc (NasdaqNM:BBII - news)
Related News Categories: biotech, medical/pharmaceutical



Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly
prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the
content, or for any actions taken in reliance thereon.

Questions or Comments?

[silberco]

Recommend this Post
Ignore this User | Report Abuse
Brief summary of BBI
by: Majortypos (32/M/Brockton, MA)
04/12/01 07:16 pm
Msg: 1828 of 1900

BBI`s primary business is producing diagnostic controls for test kits. They are,
according to many press releases, the gold standard for such products. These
products have been instrumental in shortening the time necessary to identify
diseases by helping test kit manufacturers make more sensitive and accurate test.
They also are used to ensure accuracy of testing by laboratories that are running
samples for patients. They started with this business in 1986 in Ric`s garage. The
company went public on October 31, 1996. It`s first two years as a public
company, 1996 and 1997 it posted net incomes of 481,000 and 1,005,000,
respectively. In 1998, they decided to try and develope a new technology and
took the company into an area it hadn`t been in 10 years, unprofitable. The plan
was to stay in the red for 3 years and pour money into PCT and Drug Discovery.
In October of 1999, BBI created a new subsidiary to handle the drug discovery
program with the intention of spinning it off into a seperate company, which it
accomplished in 2000.

Last February, the company announced that it had sold one of its divisions, BBI
Clinical Laboratories, generating needed cash flow and allowing BBI to reduce its
outstanding debt. They appear to be focusing on their core businesses again and
PCT development.

Recently, Panacos announced an incredible deal they had reached with the
National Cancer Institute. This deal will provide Panacos with exclusive rights to
drugs developed from a research plan that Panacos will do for them, screening
over 100,000 candidates for treating HIV/Aids. This deal could end up being a
blockbuster.

Now BBI`s focus is on returning to profitability. I suggest new investors look over
the company website and read (or reread) the various PR`s that can be found
there. The website is:

http://www.bbii.com

and the PR`s can be found at:

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=bbii&…










< Previous | Next > [ First | Last | Msg List ] Msg #:

Reply

Post




All Subject Message Text Authors

[silberco]

... hier noch ein Report vom letzten Aktionärstreffen,
werde mit dem Superlativ künftig sparsamer umgehen - also
es bleibt dabei ... IMO: exellent perspective !









Top>Business & Finance>Investments>Sectors>Healthcare>Biotechnology and Drugs> BBII (Boston
Biomedica, Inc.)
Options - Edit Public Profile - Sign In

Yahoo! Message Boards: BBII



< Previous | Next > [ First | Last | Msg List ] Msg #:

Reply

Post


Recommend this Post - This post has 1 recommendation
Stockholders` Meeting Report (1)
by: Majortypos (32/M/Brockton, MA)
06/23/01 11:17 am
Msg: 1901 of 1904

Ok, I will try and cover what they covered. I`ll probably miss some things of
importance, so bear with me. If anyone else was there and can add to or correct
anything I post, please feel free. My notes are sketchy as I was facinated by the
demonstration of PCT at one point and forgot to write some stuff down. Here
goes.

The meeting started with the standard formal meeting stuff. They elected the fellow
who was nominated for the board and then adjourned.

Then they started the informal portion of the meeting with a touching tribute to
Ric`s mom. For those that don`t know, she died just before mother`s day this year
and she was a very big supporter of her son`s company. She tended to kick him in
the butt to keep him focused on what was best for the company and its
shareholders. She sounded like a wonderful lady.

Then they got on with the business of telling us how things are going. They
currently have 4 business units (recently it was 6) with 244 employees. They sold
BBI Clinical Laboratories to Specialty Labs on 2/20/01 and they spun off Panacos
Pharmaceuticals on 11/24/00. BBI retains a 30.5% stake in Panacos. (Pana
meaning world and cos meaning cure. Didn`t know that before. I`d wondered
where that name came from.)

Next they reviewed the financials, which anyone with an annual report can do for
themselves, so I won`t go through it here. The year 2000, according to Ric, was a
disappointing year. He outlined several reasons:

Bank of Boston had been a long time supporter of BBI. They had provided a line
of credit to help BBI through their lean cash years at fairly favorable terms. When
Fleet bought them out, that changed. Fleet looked differently at the relationship and
froze the line of credit in April. This resulted in BBI having no cash and high debt.
The lack of cash resulted in a high turnover rate in 2000 and difficulty filling the
vacant positions. Recall that 2000 was a pretty good year for jobs and many
employers were offering good packages to employees. The lack of cash made
creating incentives to attract and retain employees difficult.

Additionally, cash influxes from the Paradigm warrents and sale of Panacos in May
did not materialize. The warrents were held up while the SEC reviewed the S-3
and this resulted in the stock price dropping bellow the purchase price for the
warrents. That resulted in Paradigm`s lawsuit against BBI. (See the recent news
release about the dropping of that suit.) Also, venture capital dried up early in
2000 which put Panacos`s sale on the back burner. This meant two things for the
2000 results. (1) BBI still had to consolidate Panacos`s financial statements into
their operating results in 2000 (which hurt profitability) and (2) BBI did not have
the money`s from the sale to help defray some of the costs.

These factors for the cash crunch resulted in the much discussed here convertable
debentures being issued. Those debentures can be converted for stock or paid off
depending on circumstances and what the holders of the debentures decide to do.
It can dilute the shares of a company considerably if they get converted to stock in
their entirety. The cahs they generated, though, helped BBI get through the year.

PCT, the major R&D project for BBI, ran into some unexpected difficulties which
delayed them in their project.

Finally, all of the business units missed their plans during the year.

According to Ric, 2000 was the first really bad year the company has ever had. (I
think that could be said for a lot of companies in 2000.) However, 2000 was also
the third year of a three year plan for unprofitability. The plan now, is for 2001 to
be the year they return to profitability. (I hope, for good.)



Finance Home - Yahoo!





Top>Business & Finance>Investments>Sectors>Healthcare>Biotechnology and Drugs> BBII (Boston
Biomedica, Inc.)
Options - Edit Public Profile - Sign In

Yahoo! Message Boards: BBII



< Previous | Next > [ First | Last | Msg List ] Msg #:

Reply

Post


Recommend this Post
Ignore this User | Report Abuse
Stockholders` Meeting Report (2)
by: Majortypos (32/M/Brockton, MA)
Long-Term Sentiment: Strong Buy
06/23/01 11:37 am
Msg: 1902 of 1904

In Q1 of 2001, BBI took some big strides toward`s returning to profitability. They
had an operating loss of $200,000. This loss was substancially less than the
average of $1 million/quarter in 2000. And the net income was $3.5 million, mostly
due to the sale of BBI Clinical Labs. It was a significant improvement.

Ric was optimistic for 2001 for several reasons. Most important, with the sale of
Clinical Labs, the line of credit was paid off in full. BBI now has over $2 million in
cash in the bank and no debt, other than a mortgage. It was pointed out that the
mortgage payments are less than the rental on the property would be. They have
significantly reduced their turnover and have filled their key positions. The lawsuit
was dismissed (again, see the PR`s released this week.) and the Panacos sale
which was derailed in May was rerailed in November. There are two main venture
capitalists (whose names I didn`t get) that have a history of taking such issues
public that are now funding Panacos operations. BBI stockholders would get
stock in Panacos if they decide to go public, as would BBI itself. The are no
convertable debentures outstanding anymore, they have all been paid off or
redeemed for stock. PCT is now ready. Finally, management has learned from the
mistakes made in 2000.

They then went through what all the business units do, which I`m sure most of us
have heard before, so I won`t go into detail about it. Again, I would check out the
annual report for more information here.

Their strategy going forward has several prongs. They intend to begin exploiting all
BBI units by selling services that compliment each other. It sounded like things
hadn`t been as well integrated as they could have been prior to this and the sales
force is now being trained to sell all the products the company produces instead of
just the specific products were they are working. They are also planning to
increase the utilization of their website. (Which is something I`ve been wondering
about. It seemed to me a perfect way to sell their things to customers, but I never
saw a lot done there.) They are also pursuing new markets in Rapid Tests,
Biochip, Genomics and Pharma. It truly sounded to me like they were moving on
the right track.

Continued next post...

Posted as a reply to: Msg 1901 by Majortypos
View Replies to this Message



< Previous | Next >



Finance Home - Yahoo!





Top>Business & Finance>Investments>Sectors>Healthcare>Biotechnology and Drugs> BBII (Boston
Biomedica, Inc.)
Options - Edit Public Profile - Sign In

Yahoo! Message Boards: BBII



< Previous | Next > [ First | Last | Msg List ] Msg #:

Reply

Post


Recommend this Post
Ignore this User | Report Abuse
Stockholders` Meeting Report (3)
by: Majortypos (32/M/Brockton, MA)
Long-Term Sentiment: Strong Buy
06/23/01 12:03 pm
Msg: 1903 of 1904

Next in the meeting, they focused on what Panacos is doing. There are two
compounds that Panacos is focusing on, PA-344 and PA-457 which exhibit "novel
mechanisms of action". That is a fancy way of saying they attack the virus in a way
no other drugs do. Right now, there are 14 drugs on the market to fight HIV. They
all work in one of two ways. The problem is, people become resistant to the drugs
that are out there. The estimated annual sales for a drug that can overcome that
problem is $500 million to $1 billion. Panacos has the two mentioned above in the
pipeline.

Also, most of the drugs currently on the market attack only a few of the strains of
HIV. The drugs Panacos is developing will inhibit ALL isolates of HIV-1. In
addition, they are easily synthesized, can be taken orally and are synergistic with
the drugs already being used. The compounds Panacos has are poised for clinical
development. They have 7 issued U.S. patents and several more pending. They
are expecting big things over the next 3 years.

They then demonstrated PCT. Wow, is all you can really say about it. PCT is
planning on it`s product launch in Q2 of 2002. The market here is similar to that for
the HIV drugs. Also, BBI has developed a proprietary tube for use in the machine.
The tube is not reusable and is disposable. The analogy Ric used was a razor and
the razor blades. There were a number of uses for PCT that they listed, including
genotyping, pherenzics, food safety (which is currently being done using constant
pressure but cycling pressure is showing better results), blood safety, etc. It allows
for DNA sequencing, quickly, of many types of substances. The demostration they
gave (which they are, I believe, going to be doing on a road show for PCT)
showed them using the old methods of DNA sequencing, which can take up to 4
hours/sample, vs PCT which took minutes. Also, the current methods require the
tester to use open containers, spend time grinding the material to be sequenced
with the possibility of splattering, and cleaing of the instruments after each sample.
PCT was a closed self-contained system that required little contact with the
material (imagine the first method when dealing with potentially infectious
substances and the possibility of getting sprayed in the face) and can be run on
virtually any substance. The possibilities are staggering. I talked with several
employees afterward. They told me this was the first some of them had seen of
PCT as well. (We were at the Diagnostics division which had little direct
involvement in the production of the units.) They seemed as impressed as I was.

Well, I`ve run out of notes and these posts have, I think, covered the highlights. As
I said, if anyone can add to (or correct) anything I have posted, please feel free. I
hope this helps people understand what went on Thursday. Good luck to all.

Majortypos